PAVmed Statistics
Total Valuation
PAVmed has a market cap or net worth of $7.27 million. The enterprise value is $40.95 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, before market open.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
PAVmed has 10.99 million shares outstanding. The number of shares has increased by 406.16% in one year.
| Current Share Class | 10.99M |
| Shares Outstanding | 10.99M |
| Shares Change (YoY) | +406.16% |
| Shares Change (QoQ) | +385.92% |
| Owned by Insiders (%) | 13.38% |
| Owned by Institutions (%) | 13.69% |
| Float | 9.51M |
Valuation Ratios
The trailing PE ratio is 1.25.
| PE Ratio | 1.25 |
| Forward PE | n/a |
| PS Ratio | 1.47 |
| Forward PS | 1.92 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | 2.78 |
| EV / Sales | 10.15 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.06
| Current Ratio | 0.06 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -976.89 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -95.91% |
| Return on Capital (ROIC) | -116.74% |
| Revenue Per Employee | $37,701 |
| Profits Per Employee | $137,523 |
| Employee Count | 107 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 16.15 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -83.30% in the last 52 weeks. The beta is 0.63, so PAVmed's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | -83.30% |
| 50-Day Moving Average | 0.96 |
| 200-Day Moving Average | 1.29 |
| Relative Strength Index (RSI) | 34.59 |
| Average Volume (20 Days) | 226,576 |
Short Selling Information
The latest short interest is 308,916, so 2.81% of the outstanding shares have been sold short.
| Short Interest | 308,916 |
| Short Previous Month | 286,534 |
| Short % of Shares Out | 2.81% |
| Short % of Float | 3.25% |
| Short Ratio (days to cover) | 9.07 |
Income Statement
In the last 12 months, PAVmed had revenue of $4.03 million and earned $14.72 million in profits. Earnings per share was $0.53.
| Revenue | 4.03M |
| Gross Profit | -2.37M |
| Operating Income | -55.68M |
| Pretax Income | -61.46M |
| Net Income | 14.72M |
| EBITDA | -53.83M |
| EBIT | -55.68M |
| Earnings Per Share (EPS) | $0.53 |
Full Income StatementBalance Sheet
The company has $1.25 million in cash and $34.93 million in debt, giving a net cash position of -$33.68 million or -$3.07 per share.
| Cash & Cash Equivalents | 1.25M |
| Total Debt | 34.93M |
| Net Cash | -33.68M |
| Net Cash Per Share | -$3.07 |
| Equity (Book Value) | -9.39M |
| Book Value Per Share | -0.76 |
| Working Capital | -35.43M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$45.52 million and capital expenditures -$234,000, giving a free cash flow of -$45.76 million.
| Operating Cash Flow | -45.52M |
| Capital Expenditures | -234,000 |
| Free Cash Flow | -45.76M |
| FCF Per Share | -$4.17 |
Full Cash Flow StatementMargins
Gross margin is -58.73%, with operating and profit margins of -1,380.34% and 602.97%.
| Gross Margin | -58.73% |
| Operating Margin | -1,380.34% |
| Pretax Margin | 244.84% |
| Profit Margin | 602.97% |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
PAVmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -406.16% |
| Shareholder Yield | -406.16% |
| Earnings Yield | 202.49% |
| FCF Yield | -629.63% |
Analyst Forecast
The average price target for PAVmed is $19.00, which is 2,772.26% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $19.00 |
| Price Target Difference | 2,772.26% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 124.21% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on December 7, 2023. It was a reverse split with a ratio of 0.0666667:1.
| Last Split Date | Dec 7, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.0666667:1 |
Scores
PAVmed has an Altman Z-Score of -18.73 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -18.73 |
| Piotroski F-Score | 3 |